New York Stock Exchange · LLY
Eli Lilly and Company price
Price history, key statistics, and comparable assets for Eli Lilly and Company.
$1,185.71
-0.52% ($6.23)
Historical prices
Price history
Intraday through long-term closing prices. Choose 1 day, 1 week, 1 month, 6 months, year to date, 1 year, 5 years, or all available history.
Point-in-time fields
Key statistics
- Previous close
- $1,191.94
- Open
- $1,188.00
- Day range
- $1,161.20 to $1,194.54
- 52-week range
- $625.90 to $1,249.45
- Volume
- 1.8M
- Average volume
- 3.19M
- Market cap
- 1.12T
- P/E ratio (TTM)
- 40.29
Profile
About Eli Lilly and Company
Eli Lilly and Company trades on New York Stock Exchange under LLY and is grouped under Health Technology. Figures marked unavailable are not estimated.
Editorial profile
Eli Lilly and Company overview
Eli Lilly and Company develops and manufactures prescription medicines in areas including diabetes, obesity, oncology, immunology, and neuroscience. Its business is organized around human pharmaceutical products researched, tested, manufactured, and commercialized globally. These activities place the company in Health Technology and connect LLY to the specific products, services, customers, and operating assets described in its official materials.
SourcesEli Lilly and CompanyLLY is the common stock quoted on New York Stock Exchange. Eli Lilly and Company's investor materials publish quarterly results and an annual report. This profile refers to that local security and operating group, which matters when an issuer has several venues, share classes, depositary receipts, or a name that resembles another company.
SourcesEli Lilly and CompanyEli Lilly and CompanyA genuinely distinguishing feature is that Eli Lilly has developed incretin medicines that target GIP and GLP-1 pathways for diabetes and chronic weight management. That dual-agonist mechanism is a specific part of Lilly's metabolic-medicine portfolio rather than a general drug-company attribute. This is more precise than a broad sector label: it identifies a named platform, product architecture, network, asset base, or corporate structure that separates Eli Lilly and Company from otherwise similar issuers.
SourcesEli Lilly and Company- Security type
- Common Stock
Primary sources
- Eli Lilly and Company official company profileEli Lilly and Company · Retrieved 2026-08-10
- Eli Lilly and Company investor relationsEli Lilly and Company · Retrieved 2026-08-10
- LLY listing informationEli Lilly and Company · Retrieved 2026-08-10
Contextual peers
Related assets
LLY questions
Eli Lilly and Company questions
What business does LLY represent?
LLY represents Eli Lilly and Company, which develops and manufactures prescription medicines in areas including diabetes, obesity, oncology, immunology, and neuroscience. Its business is organized around human pharmaceutical products researched, tested, manufactured, and commercialized globally.
Which products, services, or operating markets are specifically associated with LLY?
Its business is organized around human pharmaceutical products researched, tested, manufactured, and commercialized globally.
What specifically distinguishes the business behind LLY?
For Eli Lilly and Company, the asset-specific distinction is that Eli Lilly has developed incretin medicines that target GIP and GLP-1 pathways for diabetes and chronic weight management. That dual-agonist mechanism is a specific part of Lilly's metabolic-medicine portfolio rather than a general drug-company attribute.
Risk and data disclosure
Read before using this data
Glide provides this market data for informational purposes only. It is not investment advice, a recommendation, or an offer to buy or sell any asset. Prices may be delayed or incomplete. Verify market data and consider your objectives, financial situation, and professional advice before acting.